LON:HIK - Hikma Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 1,706.50 -13.00 (-0.76 %)
(As of 03/25/2019 04:00 PM ET)
Previous CloseGBX 1,719.50
Today's RangeGBX 1,704 - GBX 1,721.50
52-Week RangeGBX 1,078 - GBX 2,089
Volume319,160 shs
Average Volume822,138 shs
Market Capitalization£4.12 billion
P/E Ratio14.65
Dividend Yield2.57%
BetaN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-73992760

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.07 billion
Cash FlowGBX 127.61 per share
Book ValueGBX 699.20 per share

Profitability

Miscellaneous

Employees8,500
Market Cap£4.12 billion
Next Earnings DateN/A
OptionableNot Optionable

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Wednesday, March 13th. Shareholders of record on Thursday, April 4th will be given a dividend of GBX 0.26 per share on Wednesday, May 22nd. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, April 4th. This is an increase from Hikma Pharmaceuticals's previous dividend of $0.12. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

7 brokerages have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their predictions range from GBX 1,350 to GBX 2,250. On average, they expect Hikma Pharmaceuticals' share price to reach GBX 1,808.57 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Hikma Pharmaceuticals.

What is the consensus analysts' recommendation for Hikma Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Press coverage about HIK stock has trended positive on Monday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the near future.

Who are some of Hikma Pharmaceuticals' key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), Hawkins (HWKN), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Black Diamond Group (BDI), Och-Ziff Capital Management Group (OZM) and Accenture (ACN).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 61)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,706.50.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £4.12 billion and generates £2.07 billion in revenue each year. Hikma Pharmaceuticals employs 8,500 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  585 (Vote Outperform)
Underperform Votes:  425 (Vote Underperform)
Total Votes:  1,010
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: 52-Week High/Low

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel